Physician profile
Danny Thacker
NPI 1205139631
$10,717.40
in general payments reported to CMS, 2019-2025
34 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,839 · 2022: $2,427 · 2023: $2,458 · 2024: $2,095 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,286 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,286.15 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,405.34 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,331.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,152.75 | 2021-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $1,136.40 | 2021-2024 | Xarelto |
| Amgen INC. | $812.89 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $555.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $548.18 | 2021-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $524.53 | 2022-2025 | |
| Novo Nordisk INC | $508.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $508.16 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.25 | 2021-2024 | Jardiance |
| Esperion Therapeutics, INC. | $389.40 | 2021-2025 | Nexletol |
| Abbott Laboratories | $145.65 | 2022-2025 | Cardiomems, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $129.81 | 2021-2022 | |
| Boston Scientific Corporation | $129.11 | 2022-2024 | Bodyguardian, Watchman Access System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $128.59 | 2023-2024 | Edarbi, Edarbyclor, Edarbi |
| Vital Connect, INC | $115.47 | 2023-2025 | Vitalpatch Rtm |
| Abiomed | $82.62 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $78.93 | 2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $68.36 | 2021-2025 | Tyvaso, Tyvaso |
| Atricure, INC. | $67.59 | 2024-2025 | Atriclip Laa Exclusion System |
| Arbor Pharmaceuticals, INC. | $64.67 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $61.01 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $55.75 | 2025 | Onpattro |
| Lundbeck LLC | $46.74 | 2021 | |
| Baxter Healthcare | $42.28 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $39.47 | 2023 | |
| Edwards Lifesciences Corporation | $38.82 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $27.81 | 2021 | |
| Elutia, INC. | $23.69 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.81 | 2023 | Evkeeza |
| Medtronic, INC. | $20.28 | 2021 | |
| Scpharmaceuticals INC. | $18.14 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.